Cargando…
Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer
The tumor‐stroma ratio (TSR) has proven to be a strong prognostic factor in breast cancer, demonstrating better survival for patients with stroma‐low tumors. Since the role of the TSR as a predictive marker for neoadjuvant chemotherapy outcome is yet unknown, this association was evaluated for HER2‐...
Autores principales: | Hagenaars, Sophie C., de Groot, Stefanie, Cohen, Danielle, Dekker, Tim J. A., Charehbili, Ayoub, Meershoek‐Klein Kranenbarg, Elma, Duijm‐de Carpentier, Marjolijn, Pijl, Hanno, Putter, Hein, Tollenaar, Rob A. E. M., Kroep, Judith R., Mesker, Wilma E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362217/ https://www.ncbi.nlm.nih.gov/pubmed/34043821 http://dx.doi.org/10.1002/ijc.33700 |
Ejemplares similares
-
The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer
por: Vangangelt, Kiki M.H., et al.
Publicado: (2020) -
Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study
por: Smit, Marloes, et al.
Publicado: (2019) -
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017) -
Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016) -
Inhibition of Nox4‐dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromal‐mediated protumorigenic interactions
por: Sampson, Natalie, et al.
Publicado: (2018)